Last reviewed · How we verify
Teripalimab
Teripalimab is a Small molecule drug developed by Tianjin Medical University Cancer Institute and Hospital. It is currently in Phase 2 development. Also known as: Docetaxel /Albumin-bound Paclitaxel, Cisplatin.
Teripalimab is being studied in clinical trials for various conditions, including Esophagus Cancer, Neuroendocrine Carcinoma of the Bladder, Intrahepatic Cholangiocarcinoma (Icc), Squamous Cell Carcinoma, and Esophageal Cancer. According to ClinicalTrials.gov, Teripalimab is a PD-1 antibody, which suggests its mechanism of action is related to immune system modulation.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Teripalimab |
|---|---|
| Also known as | Docetaxel /Albumin-bound Paclitaxel, Cisplatin |
| Sponsor | Tianjin Medical University Cancer Institute and Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma (PHASE2)
- Teripalimab Plus Chemotherapy in Local Advanced Esophageal Cancer (PHASE2)
- Neoadjuvant Chemoradiotherapy Combined With PD-1 Antibody in Locally Advanced Esophageal Cancer (PHASE2)
- Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Teripalimab CI brief — competitive landscape report
- Teripalimab updates RSS · CI watch RSS
- Tianjin Medical University Cancer Institute and Hospital portfolio CI
Frequently asked questions about Teripalimab
What is Teripalimab?
Who makes Teripalimab?
Is Teripalimab also known as anything else?
What development phase is Teripalimab in?
Related
- Manufacturer: Tianjin Medical University Cancer Institute and Hospital — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Docetaxel /Albumin-bound Paclitaxel, Cisplatin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing